TAF15 Antibody

Western Blot: TAF15 Antibody [NB100-567] -

ALS proteins associate with the RNAP II/U1 snRNP machinery in an RNA-independent manner. IPs were carried out from RNase A-treated or untreated nuclear extract using an RNAP II or a negative control antibody (EIF4A3) followed by westerns with the indicated antibodies.

Western Blot: TAF15 Antibody [NB100-567] -

Western Blot: TAF15 Antibody [NB100-567] - FET proteins & MATR3 associate with U1 snRNP. (a) Immunoprecipitations (IPs) were carried out with antibodies to FET proteins or MATR3 followed by analysis on a Coomassie-stained gel. Molecular weight markers & protein identified by mass spectrometry are indicated. (b) IPs were carried out from nuclear extract using a negative control antibody (EIF4A3) or an antibody to the SNRPC subunit of the U1 snRNP followed by Westerns with the indicated antibodies. (c) IPs were carried out with the indicated antibodies from nuclear extract treated with a U1 snRNA AMO or a negative control AMO followed by Western using the SNRPC antibody. (d) Same as (c) except that total RNAs from the IPs were examined on a denaturing gel stained with ethidium bromide. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29884807), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Simple Western: TAF15 Antibody [NB100-567] -

Simple Western: TAF15 Antibody [NB100-567] - Autophagic clearance of aberrantly accumulated cytoplasmic FUS restores protein homeostasis & ameliorates survival of SL P525L iPSC-derived neurons. a Confocal micrographs showing FUS-eGFP distribution before & after Torkinib treatment (above). Arrowhead indicates FUS-eGFP cytoplasmic accumulation in untreated neurites; arrow shows reduced FUS-eGFP cytoplasmic signal following torkinib treatment. Quantification of cytoplasmic FUS-eGFP signal intensity in acquired images (below) confirms clearance of mislocalized FUS-eGFP protein. Scale bar = 10 µm. b FRAP analysis performed on untreated versus torkinib-treated neurons shows comparable dynamics of FUS-eGFP recovery. n = 3. Error bars indicate SEM. CHX = cycloheximide. c WES capillary electrophoresis & d corresponding quantification of the indicated proteins in P525L SL neurons before & after torkinib treatment. Autophagy stimulation restores physiological levels. n = 4. Error bars indicate SEM. * & ** Correspond to p < 0.05 & 0.01, respectively. e 6 h of torkinib reduces apoptotic cell death identified by cleaved Caspase 3 staining. Scale bar = 50 µm Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30937520), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Simple Western: TAF15 Antibody [NB100-567] -

Simple Western: TAF15 Antibody [NB100-567] - The cytoplasmic mislocalization induced by P525L causes reduced FUS binding to several ALS-associated RBPs, promoting aggregation. a, b Western blot analysis of FUS protein interactors in a LL & b SL neurons after FUS-eGFP immunoprecipitation reveals differential interactions with several ALS-associated partners. n = 4. Error bars indicate SEM. *, **, & *** Correspond to p < 0.05, 0.01, & 0.001, respectively. c In vitro phase separation assay showing fibrillization of purified P525L LL FUS-eGFP protein in the presence or absence of distinct RBPs. Investigated RBPs effectively prevent FUS fibril formation. d Fluorescence recovery after photobleaching (FRAP) was used to assess the dynamics of P525L LL FUS at the tested conditions for the indicated time points. RBPs promote the maintenance of a liquid-like behavior. e Co-localization of P525L LL FUS with the reported RBPs. Scale bar 5 µm Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30937520), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Simple Western: TAF15 Antibody [NB100-567] -

Simple Western: TAF15 Antibody [NB100-567] - The cytoplasmic mislocalization induced by P525L causes reduced FUS binding to several ALS-associated RBPs, promoting aggregation. a, b Western blot analysis of FUS protein interactors in a LL & b SL neurons after FUS-eGFP immunoprecipitation reveals differential interactions with several ALS-associated partners. n = 4. Error bars indicate SEM. *, **, & *** Correspond to p < 0.05, 0.01, & 0.001, respectively. c In vitro phase separation assay showing fibrillization of purified P525L LL FUS-eGFP protein in the presence or absence of distinct RBPs. Investigated RBPs effectively prevent FUS fibril formation. d Fluorescence recovery after photobleaching (FRAP) was used to assess the dynamics of P525L LL FUS at the tested conditions for the indicated time points. RBPs promote the maintenance of a liquid-like behavior. e Co-localization of P525L LL FUS with the reported RBPs. Scale bar 5 µm Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30937520), licensed under a CC-BY license. Not internally tested by Novus Biologicals.